Argenx’s Vyvgart Shot Gains US Approval for Rare Nerve Disorder

Argenx SE’s Vyvgart Hytrulo shot gained US approval to treat a rare nervous system disorder, a win for the biotechnology firm after a series of setbacks.

Vyvgart Hytrulo gained approval to treat chronic inflammatory demyelinating polyneuropathy, a condition that leads to muscle weakness and loss of sensation in the arms and legs. The drug has US clearance for generalized myasthenia gravis, another rare disease that affects the neuromuscular system. It’s also approved in an infused form called simply Vyvgart.